61,009 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Purchased by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 61,009 shares of the biopharmaceutical company’s stock, valued at approximately $1,273,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CPRX. GAMMA Investing LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares in the last quarter. XTX Topco Ltd increased its position in shares of Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 773 shares during the period. Sei Investments Co. raised its stake in shares of Catalyst Pharmaceuticals by 1.3% in the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock worth $1,308,000 after buying an additional 1,098 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 2.4% in the third quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock valued at $1,436,000 after buying an additional 1,704 shares during the period. Finally, Summit Global Investments boosted its stake in Catalyst Pharmaceuticals by 2.6% during the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock valued at $1,537,000 after buying an additional 1,923 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $32.86.

Catalyst Pharmaceuticals Stock Up 3.9 %

Shares of Catalyst Pharmaceuticals stock opened at $23.06 on Thursday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.12 and a 12 month high of $24.27. The stock has a market cap of $2.75 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 3.26 and a beta of 0.75. The business has a fifty day simple moving average of $21.79 and a 200-day simple moving average of $20.13.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.